Анемия у больных с сердечной недостаточностью Medline.ru - медико-биологический информационный портал Медлайн.ру

1. Чернов В.М. Анемия - скрытая эпидемия. - М.: МегаПро., 2004. - 76 с.

2. Kannel W.B. Epidemiology and prevention of cardiac failure: Framingham Study insights // Eur. Heart. J. – 1987. – Vol. 8. - Supp l. - P. F23–26.

3. Silverberg D.S., Wexler D., Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? // J. Nephrol. – 2004. – Vol.17. – P. 749–761.

4. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics // J. Card. Fail. – 2004. - Vol.10. – P. S1-4.

5. Nutritional Anaemias: Report of a WHO Scientific Group: World Health Organization; 1968.

6. Weiss G., Goodnough LT. Anemia of chronic disease // N. Engl. J. Med. – 2005. - Vol. 352. - P. 1011-1023.

7. Volpe M, Tritto C, Testa U. et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles // Am. J. Cardiol. – 1994. – Vol.74. - P. 468–473.

8. Androne A.S., Katz S.D., Lund L. et al. Haemodilution is common in patients with advanced heart failure // Circulation. – 2003. – Vol. 107. – P. 226–229.

9. Caramelo C., Just S., Gil P. Anemia in heart failure: pathophysiology, pathogenesis, treatment, and incognitae // Rev. Esp. Cardiol. – 2007. - Vol. 60. - P. 848-860.

10. Sandhu A., Soman S., Hudson M., Besarab A. Managing anemia in patients with chronic heart failure: what do we know? // Vasc. Health. Risk. Manag. – 2010. - Vol. 6. – P. 237-252.

11. Atanasiu V., Manolescu B., Stoian I. Hepcidin: central regulator of iron metabolism // Eur. J. Haematol. – 2007. – Vol. 78. – P. 1-10.

12. Ganz T. Hepcidin: a peptide hormone at the interface of innate immunity and iron metabolism // Curr. Top. Microbiol. Immunol. – 2006. – Vol. 306. – P. 183-198.

13. Le Meur Y., Lorgeot V., Comte L. et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements // Am J Kidney Dis. – 2001. – Vol. 38. – P. 510–517.

14. Volpe M., Tritto C., Testa U. et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles // Am. J. Cardiol. - 1994. – Vol. 74. – P. 468-73.

15. Jensen J.D., Eiskjaer H., Bagger J.P., Pedersen E.B. Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma rennin // J. Intern. Med. – 1993. – Vol. 233. – P. 125-130.

16. Marathias K.P., Agroyannis B., Mavromoustakos T. et al. Hematocrit-lowering effect following inactivation of rennin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers // Curr. Top. Med. Chem. – 2004. – Vol. 4. – P. 483- 486.

17. Lupon J., Urrutia A., González B. et al. Prognostic significance of hemoglobin levels in patients with heart failure // Rev. Esp. Cardiol. – 2005. – Vol. 58. – P. 48-53.

18. Horwich T.B., Fonarow G.C., Hamilton M.A. et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure // J. Am. Coll. Cardiol. - 2002. – Vol. 39. – P.1780–1786

19. Vaziri N.D. Erythropoietin and transferrin metabolism in nephrotic syndrome // Am. J. Kidney. Dis. – 2001. – Vol. 38. – P. 1-8

20. Tong E.M., Nissenson A.R. Erythropoietin and anemia // Semin. Nephrol. – 2001. – Vol. 21. – P.190–203.

21. Fisher J.W. Erythropoietin: physiology and pharmacology update // Exp. Biol. Med. – 2003. – Vol. 228. – P. 1-14.

22. Jelkmann W. Molecular biology of erythropoietin // Intern. Med. – 2004. – Vol. 43. – P. 649- 659.

23. Caramelo C., Pena Deudero J.J., Castilla A. et al. Response to hypoxia. A systemic mechanism based on the control of gene expression // Medicina (Buenos Aires). – 2006. – Vol. 66. – P. 155-164.

24. Nangaku M., Eckardt K.U. Pathogenesis of renal anemia // Sem. Nephrol. – 2006. – Vol. 26. – P. 261-268.

25. Eckardt K.U., Rosenberger C., Jürgensen J.S., Wiesener M.S. Role of hypoxia in the pathogenesis of renal disease // Blood Purif. – 2003. – Vol. 21. - P. 253-257.

26. Chatterjee B., Nydegger U.E., Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists // Eur. J. Heart. Fail. – 2000. – Vol. 2. – P. 393-398.

27. Diskin C.J. Erythropoietin, haemoglobin, heart failure, and mortality // Eur. Heart. J. – 2008. – Vol. 29. – P. 2695–2696.

28. Felker G.M., Kirkwood F.A., Gattis W.A., Christopher M.O. Anemia as a risk factor and therapeutic target in heart failure // J. Am. Coll. Cardiol. – 2004. – Vol. 44. – P. 959-966.

29. Belonje A., Voors A., van der Meer P. et al. Veldhuisen endogenous erythropoietin and outcome in heart failure // Circulation. – 2010. – Vol. 121. - P. 245-251.

30. Ronco C., Haapio M., House A.A. et al. Cardiorenal syndrome // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1527–1539.

31. Ronco C., House A.A., Haapio M. Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus // Nat. Clin. Pract. Nephrol. – 2008. – Vol. 4. – P. 310–311.

32. Efstratiadis G., Konstantinou D., Chytas I., Vergoulas G. Cardio-renal anemia syndrome // Hippokratia. – 2008. – Vol. 12. – P. 11-16.

33. Gil P., Justo S., Castilla M.A. et al. Cardio-renal insufficiency: the search for management strategies // Curr. Opin. Nephrol. Hypertens. – 2005. – Vol. 14. – P. 442-447.

34. Horwich T.B., Fonarow G.C., Hamilton M.A. et al. Anemia Is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure // J. Am. Coll. Cardiol. – 2002. – Vol. 39. – P. 1780–1786.

35. Kosiborod M., Curtis J.P., Wang Y. et al. Anemia and outcomes in patients with heart failure: a study from the national heart care project // Arch. Intern. Med. - 2005. – Vol. 165. – P. 2237-2244.

36. Silverberg D.S., Wexler D., Blum M. et al. The Use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations // J. Am. Coll. Cardiol. – 2000. – Vol. 35. – P. 1737-1744.

37. Silverberg D.S., Wexler D., Blum M., et al. Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure // Kidney Blood Press. Res. – 2005. – Vol. 28. – P. 41–47.

38. Zilberman M., Silverberg D.S., Bits I., et al. Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure // Am. Heart. J. – 2007. – Vol. 154. – P. 870–876.

39. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 2485–2489.

40. Silverberg D.S., Wexler D., Blum M., Iaina A. The cardio-renal-anemia sydrome. Correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations // Clin. Nephrol. – 2003. – Vol. 60. - Suppl. 1S. – P. 93- 102.

41. Bolger A.P., Bartlett F.R., Penston H.S. et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 1225- 1227.

42. Beck-da-Silva L., Rohde L.E., Pereira-Barretto A.C. et al. Rationale and design of the IRONHF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia // J. Card. Fail. – 2007. – Vol. 13. – P. 14-17.

43. Okonko B.S., Anker S.D. Anemia in chronic heart failure: pathogenetic mechanisms // J. Cardiac Failure. – 2004. – Vol. 10. – Suppl. – P.5-9.

44. Silverberg D.S., Wexler D., Blum M., et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases // Perit. Dial. Int. – 2001. – Vol. 21. – Suppl. 3. – P. S236–240.

45. van der Meer P., Lipsic E., Henning R.H. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction // J. Am. Coll. Cardiol. – 2005. – Vol. 46. – P. 125–133.

46. van der Meer P., Voors A.A., Lipsic E. et al. Erytropoietin in cardiovascular diseases // Eur. Heart. J. – 2004. – Vol. 25. – P. 285-291.

47. Arnold J.M., Howlett J.G., Dorian P. et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers // Can. J. Cardiol. – 2007. – Vol. 23. – P. 21–45.

48. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group // N. Engl. J. Med. – 1999. – Vol. 340. – P. 409–417.

49. Rao S.V., Jollis J.G., Harrington R.A. et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes // JAMA. – 2004. – Vol. 292. – P. 1555– 1562.

50. Agarwal A.K., Katz S.D. Future directions in management of anemia in heart failure // Heart Fail. Clin. – 2010. – Vol. 6. – P. 385-395.